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Available online 10 June 2015AbstractBackground: The epidemiological features of snakebite are fragmented and inadequate in most countries. The true impact of snakebite is also
very likely to be underestimated, and reliable information on its incidence, morbidity, and mortality is limited worldwide.
Methods: We perform a nationwide epidemiological study of snakebite by extracting claim record data from Taiwan's National Health Insurance
database to explore the epidemiology of venomous snakebite from years 2005 to 2009.
Results: A total of 4647 snakebites were reported in 2005e2009. The nationwide annual incidence of snakebite was 40.49 per million persons.
Hemorrhagic-type snakebites (Viridovipera stejnegeri and Protobothrops mucrosquamatus) accounted for 71.78% of the cases, while
neurotoxic-type snakebites (Naja atra and Bungarus multicinctus) accounted for 19.21%. Only a few cases of snakebites were caused by
Deinagkistrodon acutus (0.73%). Although the east part of Taiwan accounted for only one-sixth of the total number of cases, the same area had
the highest incidence of snakebite, about seven times the national incidence. Fifty-nine percent (n ¼ 2747) of victims were between the age of 41
years and 70 years, and mostly in the age group of 51e60 years (n ¼ 1026, 22%). The highest incidence (130.4 per million persons) was in the
age group of 71e80 years. In general, snakebite victims suffered minor injuries. Overall, hospital admission was 35.8%, and only about 3.6%
patients were needed to be admitted to the intensive care unit. During this study period, only two cases of mortality were documented.
Conclusion: In this population-based study, the annual incidence of venomous snakebite was 40 per million people. Cases of venomous
snakebite are geographically unevenly distributed in Taiwan. Due to effective antivenom therapy, the outcome of the snakebite patients was
favorable.
Copyright © 2015, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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There are very few wide-scaled epidemiological studies of
snakebite. The true impact of snakebite is often underestimated,
and trustworthy information on incidence, morbidity, and
mortality is inadequate worldwide.1,2 Population-based studies* Corresponding author. Department of Emergency Medicine, National
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2211-5587/Copyright © 2015, Taiwan Society of Emergency Medicine. Publishedof incidence and mortality from snakebite are currently lacking
and are urgently needed to investigate the full scale of the dis-
ease.3 A Pacific subtropical island with mountains and forests,
Taiwan is an ideal habitat for several species of snakes. How-
ever, similar to its neighboring tropical countries, a nationwide
epidemiological study on snake envenomation is lacking.
Epidemiological studies of snakebite in Taiwan were mostly
conducted in a single hospital setting.4 Therefore, it is very
difficult to make conclusions pertaining to the need of anti-
venoms nationwide, the efficacy of such a therapy, and the scale
of progress made on snakebite treatments.5by Elsevier Taiwan LLC. All rights reserved.
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release deadly toxins, which can result in life-threatening
complications. The four species of snakes in Taiwan that
secrete hemorrhagic venom are Viridovipera stejnegeri
(formerly Trimeresurus stejnegeri, Taiwan bamboo viper or
green habu), Protobothrops mucrosquamatus (formerly Tri-
meresurus mucrosquamatus, Taiwan habu), Deinagkistrodon
acutus (hundred-pacer), and Daboia russelii siamensis. These
venoms cause local tissue swelling that can progress to severe
compartment syndrome on the limb where venom was injec-
ted. In patients with severe tissue swelling, surgical interven-
tion such as debridement, fasciotomy, or graft may be needed.
Snakes releasing neurotoxic venoms are Naja atra (Chinese or
Taiwan cobra) and Bungarus multicinctus (Taiwan banded
krait). These venoms can cause respiratory distress due to
muscle paralysis and other neurological manifestations such as
diplopia, dysarthria, and extremity paralysis. Between the two
species, B. multicinctus venoms result in a more profound
neurological deficit than the venoms of N. atra. However, N.
atra venoms can result in tissue damages as well as neuro-
logical deficits. Surgical intervention such as debridement,
fasciotomy, or skin graft may also be needed in the treatment
of N. atra snakebite.
In the 1960s, Taiwan began to develop antivenoms for some
venomous snake species, but only about 15% of the cases were
given antivenoms. At that time, most cases of snakebites were
treated with herbal medicine instead.6 In 1980s, the F(ab0)2 of
horse immunoglobulin G antivenoms were developed by the
Vaccine Center, Center for Disease Control, Taipei,
Taiwan.7e9 At present, four antivenom regimens are available
in the country. The bivalent antivenom FH is effective against
V. stejnegeri and P. mucrosquamatus, and another bivalent
antivenom FN is effective against B. multicinctus and N. atra.
The antivenom FA is effective against D. acutus. The anti-
venom FDrs that is effective against D. russelii siamensis was
not developed until mid-2008.
Taiwan launched a single-payer National Health Insurance
(NHI) program on March 1, 1995. According to the Bureau of
NHI, the coverage of NHI has surpassed 96% of the national
population, whereas the number of cooperating medical fa-
cilities has reached 95% in 2009.10,11 The NHI database
contains registration files and original claim data for reim-
bursement. After scrambling patients' identities, the database
is provided to scientists in Taiwan for research purposes. With
its nationwide coverage, it is pertinent for epidemiological
studies and has been used widely in academic studies.12 The
purpose of this study was to perform a nationwide epidemio-
logical study of venomous snakebite from 2005 to 2009. We
intended to estimate the comprehensive epidemiological fea-
tures of snake envenomation.
2. Materials and methods2.1. Ethics statementThis study was approved by the Chang Gung Memorial
Hospital Research Ethical Committee, Taoyuan, Taiwan(100e3049B). The identification of each patient was previ-
ously scrambled by the NIH Bureau; therefore, no informed
consent was needed.2.2. Data source and study methodsWe used NHI claim data in the period of 2005e2009 for
descriptive epidemiology studies. This data set included
complete outpatient visits, hospital admissions, disease diag-
nosis, prescriptions, procedures, interventions, and vital sta-
tuses for the whole insured population. We established the
longitudinal medical history of each beneficiary by linking
several computerized administrative claim data sets to track
the outcomes of the snakebite episodes. In the NHI database,
each drug has its own drug code. By tracing the antivenom
drug codes (drug codes J000006212 for FH, J000009212 for
FN, and J000010209 for FA), we are able to retrieve cases
treated by these antivenoms. As FDrs antivenom was not
available prior to mid-2008, the cases that used FDrs anti-
venom were not included in this study. Patients who received
only one type of antivenom for treatment were classified as FH
group, FN group, or FA group, depending on the type of an-
tivenom received. Patients who received more than one type of
antivenom in a single episode of snakebite were classified as
the mixed group.
Variables were extracted from the NHI database for
descriptive and analytic epidemiological studies. Recorded
variables were the following: patient's age, gender, the month
of attack, and the location of the treating hospital. In the NHI
system, Taiwan Island is divided into six districts: District 1
(the Taipei district), District 2 (the North district), District 3
(the Central district), District 4 (the South district), District 5
(the Kaohsiung district), and District 6 (the East district).
3. Results
A total of 4647 snakebite cases were reported in
2005e2009. There were 3340 (71.87%) episodes in the FH
group, 893 (19.21%) in the FN group, 380 (8.10%) in the
mixed group, and only 34 (0.73%) in the FA group. Most
antivenom regimens used in the mixed group were the com-
bination of FH and FN. The nationwide annual incidence of
venomous snakebite was 40.49 per million persons (Table 1).
The national annual incidence of the FH group was 29.10 per
million persons, FN group was 7.78 per million persons, FA
group was 0.30 per million persons, and mixed group was 3.31
per million persons. The geographic district incidences of
snakebite are shown in Table 1 and Figure 1. District 1 had the
highest case number. However, the incidence rate in District 1
was slightly less than the national incidence rate due to Dis-
trict 1 being the most densely populated area in the country.
Although District 6 accounted for only one-sixth of the total
cases, it had the highest incidence rate (about 7 times the
national incidence rate). Regardless of the type of snakebite,
District 6 had the highest incidence rate among all districts.
District 3 had the lowest incidence of total snakebites but
relatively high incidence rate in the FN group. FA group
Table 1
Case numbers and incidences (per million population) of snakebites in different regions of Taiwan during 2005e2009.
District FH FN FA Mixed Total
Case no. Incidence Case no. Incidence Case no. Incidence Case no. Incidence Case no. Incidence
1 1099 30.22 81 2.23 7 0.19 96 2.64 1283 35.28
2 479 28.26 133 7.85 2 0.12 93 5.49 707 41.71
3 396 17.78 203 9.11 4 0.18 51 2.29 654 29.37
4 345 20.17 142 8.30 1 0.06 42 2.46 530 30.99
5 416 22.77 187 10.24 4 0.22 37 2.03 644 35.25
6 605 209.25 147 50.87 16 5.52 61 21.05 829 286.70
Total 3340 29.10 893 7.78 34 0.30 380 3.31 4647 40.49
FA ¼ cases receiving antivenom FA regimen; FH ¼ cases receiving antivenom FH regimen; FN ¼ cases receiving antivenom FN regimen; Mixed ¼ cases receiving
more than one antivenom regimen.
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the cases found in District 6.
The majority of the snakebite victims was male (n ¼ 3279,
70.5%). The ratios between male and female were 2.28 for the
FH, 3.09 for the FN, 4.66 for the FA, and 1.96 for the mixed
groups. The average age of all snakebite victims was 40.5
years. The case numbers and incidences among different age
groups are shown in Figure 2. Fifty-nine percent (n ¼ 2747) of
victims were in the age group of 41e70 years, and most cases
were in the age group of 51e60 years (n ¼ 1026, 22%,Figure 1. Incidences of snakebites in different regions of Taiwan in
2005e2009: (A) total venomous snakebites, and venomous snakebites in the
(B) FH, (C) FN, and (D) FA groups. The darker the color, the higher the
relative incidence in the region.
Figure 2. Age-wise distribution of snakebite victims in Taiwan during
2005e2009. Both the incidences and case numbers in different age groups are
shown.Figure 2). However, when the incidences of different age
groups were calculated, the highest incidence (130.4 per
million persons) was in the age group of 71e80 years
(Figure 2). Throughout the years, 77% (n ¼ 3584) of snakebite
incidence occurred from April to November, with the peak
being in August (Figure 3). Snakebites in the FH group were
in plateau status from May to November, whereas the case
numbers in the FN group presented peaks in August
(Figure 3).
The overall outcome of snakebite victims was favorable.
General ward admission rate was 35.8%, and only about 3.6%
patients needed to be admitted to the intensive care unit. The
FA group had the highest intensive care unit admission rate,
and the FH group had the lowest. There were only two cases of
mortality during the study period (Table 2).
4. Discussion4.1. Nationwide incidence and geographic differences of
snakebitesIn this study, a comprehensive epidemiological study of
snakebite in Taiwan was demonstrated. This is the first
nationwide population-based snakebite study in Taiwan, and to
the best of our knowledge, there has been no nationwideFigure 3. Month-wise distribution of snakebite incidences in Taiwan during
2005e2009. The case numbers in different months of the year are shown.
FA ¼ case numbers of the FA group; FH ¼ case numbers of the FH group;
FN ¼ case numbers of the FN group; Mixed ¼ case numbers of the mixed
group; Total ¼ overall case numbers.
Table 2
Outcome of snakebite patients in 2005e2009.
Group Case no. Ward ICU Death
FH 2644 837 (31.7) 42 (1.6) 0
FN 736 222 (30.2) 45 (6.1) 1 (0.1)
FA 28 12 (42.9) 4 (14.3) 0
Mixed 1239 591 (47.7) 78 (6.3) 1 (0.08)
Total 4647 1662 (35.8) 169 (3.6) 2 (0.04)
Data are presented as n (%) unless otherwise indicated.
FA ¼ cases receiving antivenom FA regimen; FH ¼ cases receiving antivenom
FH regimen; FN ¼ cases receiving antivenom FN regimen; ICU ¼ admission
to intensive care unit; Mixed ¼ cases receiving more than one antivenom
regimen; Ward ¼ admission to general ward.
41C.-K. Chen et al. / Journal of Acute Medicine 5 (2015) 38e42studies on the incidence of snakebite in today's literature.3
Venomous snakebites were geographically unevenly distrib-
uted in Taiwan. The incidence rate in the east side of the island
was about seven times the national incidence. This area of the
island consists of mountains and forests, and is less populated.
Our study reflected a need for any national health authority to
acknowledge the geographic difference in dealing with
snakebites, thus allocating medical resources accordingly.
Another important finding discovered in this study was the age
distribution of snakebite patients. The peak incidence, which
was more than three times the national incidence, was in the
age group of 71e80 years. The incidence in the age group of
>81 years was more than two times the national incidence.
This showed that the elderly people are most susceptible to
snakebite in Taiwan. Snakebite prevention and education
should be targeted to the elderly, especially those who live and
work in rural areas.
Not only are snakes geographically distributed unevenly
across the island, but also different species of snake become
more active than others as time changes. The case numbers of
snakebites differed in different regions and times, due to the
different species of snakes and their population distribution. In
this study, the FH group snakebite accounted for about 72% of
the total cases, while the FN group accounted for 19%. In
1969, a survey on different snakebite groups was conducted
throughout Taiwan. That report showed 558 cases in the FH
group, 252 in the FN group, and 37 in the FA group.6 The
number of cases in the FN group decreased in our study
compared to that of 40 years ago. Cases of snakebites caused
by D. acutus were even fewer than those 40 years ago. This
showed that throughout the years, the population of different
species of snakes has changed.4.2. Antivenom efficacy and safetyAt present, the principal treatment of snakebite in Taiwan is
antivenom therapy. Among the 4647 cases collected during the
study period, there were only two cases of mortality. Forty
years ago, the mortality rate from snakebite in Taiwan was
about 1.4% when the use of antivenom therapy was uncom-
mon.6 This decrease in mortality rate showed the efficacy of
antivenom treatment. As Taiwan is a part of Southeast Asia,
many of its venomous snakes often have species under thesame family inhabiting other countries in this region.5 The low
mortality rate from snakebite seen in Taiwan might be
explained by the routine use of antivenom here.3,5
Sometimes, it is difficult to identify the species of the snake
solely from the clinical presentation of the patient, especially
when the snake was not available for identification. If the
patient also failed to identify the culprit snake, then the correct
diagnosis could be hard to achieve. Thus, in practice, different
kinds of antivenoms may be administered to the patient. In our
study, 380 (8.1%) cases received at least two types of anti-
venoms. The clinical presentations of different snakebites
could be very similar. In some studies, these unidentified cases
accounted for 12e45% of the total cases.13e16 At the present
time, there is a method of using blood assay to detect the N.
atra venom, but it is not commercially available.4 Other types
of venoms cannot be identified by any laboratory test. Further
research is needed to assure a correct diagnosis and improve
the treatment.4.3. LimitationsUsing our database, we were unable to identify which snake
species in the FH or FN group caused the snakebite. The
incidence of snakebite could be underestimated due to
neglected cases of dry bites, in which situation antivenom
therapy would not be used. Due to the time of data collection,
patients bitten by D. russelii siamensis were not included in
this study. However, the number of cases in this category
should be very small (the annual attacks ranged from 1 to
3).4,6,15,17 Therefore, the underestimation of D. russelii sia-
mensis attacks should have minimal influence on the epide-
miology result of this study.
5. Conclusion
In this nationwide study, the annual incidence of venomous
snakebite was 40 per million people. The geographic distri-
bution of venomous snakebite is uneven in Taiwan. Due to an
effective antivenom therapy, the outcome of the snakebite
patients was favorable.
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